EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective

Andrew Carr iD, Nicola E Mackie, Roger Paredes, Kiat Ruxrungtham

Antiviral Therapy · 2023-10 · 28 (5)

DOI: 10.1177/13596535231201162 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antiviral Therapy, online erschienen am 25.09.2023. Verfasst von Andrew Carr und 3 weiteren Autor:innen. Beteiligte Einrichtung: HIV and Immunology Unit, St Vincent's Hospital, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Anti-Retroviral Agents. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Contemporary antiretroviral therapy (ART) regimens have high barriers to the development of drug resistance. However, resistance to earlier antiretrovirals and uncommon cases of resistance to contemporary ART illustrate the continued need for good clinical management of HIV drug resistance. Here, we describe HIV drug-resistance mechanisms, the interaction of HIV drug-resistant mutations and the patterns of drug resistance to contemporary ART. We then provide guidance on the management of HIV drug resistance, including how to limit the development of resistance and manage virologic failure that is complicated by resistance. To complement this, links to resources and treatment guidelines are provided that can assist with the interpretation of HIV drug resistance test results and optimal ART selection in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Retroviral AgentsHumansMutation

Stichwörter der Autor:innen

HIVclinicalmanagementresistancevirologic failure

Substanzen

Anti-Retroviral Agents

Autor:innen und Institutionen

  • HIV and Immunology Unit, St Vincent's Hospital, Sydney, NSW, Australia.
  • University of New South Wales, Sydney, NSW, Australia.
  • Imperial College Healthcare NHS Trust, London, UK.
  • Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • IrsiCaixa AIDS Research Institute, Barcelona, Spain.
  • Chula Vaccine Research Center (Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Andrew Carr

Förderung

  • Gilead Sciences Inc.

Zitieren

APA

Carr, A., Mackie, N. E., Paredes, R., & Ruxrungtham, K. (2023). HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective. Antiviral Therapy, 28(5). https://doi.org/10.1177/13596535231201162

Vancouver

Carr A, Mackie NE, Paredes R, Ruxrungtham K. HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective. Antiviral Therapy. 2023;28(5). doi:10.1177/13596535231201162

BibTeX
@article{Carr2023,
  author = {Carr, Andrew and Mackie, Nicola E and Paredes, Roger and Ruxrungtham, Kiat},
  title = {HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective},
  journal = {Antiviral Therapy},
  year = {2023},
  volume = {28},
  number = {5},
  doi = {10.1177/13596535231201162}
}
Kostenlos starten →